Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Accounts Receivable : HK$0.0 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Sichuan Kelun-Biotech Biopharmaceutical Co's accounts receivables for the quarter that ended in Dec. 2023 was HK$0.0 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Sichuan Kelun-Biotech Biopharmaceutical Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$6.88.

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Receivable Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Receivable Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Receivable

0.18

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Accounts Receivable	Get a 7-Day Free Trial			-	0.49	-	-	-

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Sichuan Kelun-Biotech Biopharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Sichuan Kelun-Biotech Biopharmaceutical Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2765.447	+	0.75 * 0	+	0.5 * 68.943	-	1290.941
-	0	-	0)	/	219.195
=	6.88

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Executives

Liu Gexin	2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Merck & Co., Inc.	2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc	2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si	2101 Beneficial owner
Li Jun	2201 Interest of corporation controlled by you
Zhou Quan	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p.	2201 Interest of corporation controlled by you
Victory Rhythm Limited	2201 Interest of corporation controlled by you
Wealthy Linkage Limited	2101 Beneficial owner
Ho Chi Sing	2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines